CA2765621A1 — Crystalline freebase forms of a biphenyl compound
Assigned to Theravance Biopharma R&D IP LLC · Expires 2011-01-20 · 15y expired
What this patent protects
The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1 -(2-{ [4-(4-carbamoylpiperidin- 1 -ylmethyl)benzoyl]methylamino } ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or pre…
USPTO Abstract
The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1 -(2-{ [4-(4-carbamoylpiperidin- 1 -ylmethyl)benzoyl]methylamino } ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases that may be useful to treat a pulmonary disorder.
Drugs covered by this patent
- Yupelri (REVEFENACIN) · Mylan Ireland Ltd
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.